CIC:	Unique Patient Number (UPN):	SCT Date	e:		·
			VVVV	mm	dd

## Annual FOLLOW UP

## **CALM - LYMPHOMA**

FOLLOW UP						
2012-2014						
EBMT Unique Identification Code (UIC): (if known)						
Hospital Unique Patient Number (U	IPN):					
Initials:			(first name(s)_surna	ame(s))		
Date of birth:	dd					
Sex: ☐ Male ☐ Female						
Date of last HSCT for this patient:						
	уууу	mm dd				
	PA	ATIENT LAST	SEEN			
DATE OF LAST CONTACT OR D	EATH:	уууу mm	dd			
GRAFT ASSESSMENT GRAFT LOSS (EQUIVALENT TO APLASIA IF AUTO)  No						
☐ Yes: Date graft loss:		=				
yyyy mm dd  ☐ Not evaluated						
COMPLICATIONS SINCE LAST REPORT						
INFECTION RELATED COMPLICATIONS  No complications Yes:						
Туре	Yes	Site	Pathogen	Date		
Bacteremia						
Fungemia						
Viremia						
Parasites						
Septic shock						
ARDS						
Multiorgan failure due to infection						
Pneumonia						
Hepatitis						
CNS Infection						
Other:						

yyyy/mm/dd

CIC: Unique Patient Number (UPN):		SC1	SCT Date:				
·	, ,		У	УУУ	mm	dd	
NON INFECTION RELATED COMPLICATION	IS						
□ No complications							
Yes:							
	ı	I					
Туре	Yes	Date					
ldispathia masumania sundususa							
Idiopathic pneumonia syndrome	Ш						
VOD							
EBV lymphoproliferative disease							
Cataract							
Haemorrhagic cystitis, non infectious							
ARDS, non infectious			_				
Multiorgan failure, non infectious							
HSCT-associated microangiopathy							
Renal failure requiring dialysis							
Haemolytic anaemia due to blood group							
Aseptic bone necrosis	П						
Other:	П						
		yyyy/mm/dd	<del></del>				
SECONDARY MALIGNANCY, LYMPHOPRO	LIFERAT	IVE OR MYELOPROL	IFERATI	VE DISC	ORDER		
DIAGNOSED							
☐ Previously reported							
☐ Yes, date of diagnosis:							
yyyy mm	dd 			<b>7</b>			
Diagnosis: ☐ AML ☐ MDS ☐ No, at date of this follow-up	☐ EBA	y lymphoproliterative dis	soraer <b>L</b>	<b>」</b> Otner	•		
		0.001051.405	<b>5011</b>	<b>0</b>			
ADDITIONAL THERAPIES SINCE LAST FOLLOW UP							
DISEASE TREATMENT							
□ No							
☐ Yes: ☐ Planned (planned before HSCT too	k place)						
☐ Not planned (for relapse/progression)	on or persi	stent disease)					
Chemo/drug/agent:(including MoAB, vaccination	oto \				Unknowr	า	
· · · · · · · · · · · · · · · · · · ·		☐ Unknown					
Other treatment $\square$ No	☐ Yes,	specify:			Unknowi	n	
☐ Unknown		. ,					
FIRST EVIDENCE OF RELAPSE OR PROGRESSION SINCE LAST HSCT							
RELAPSE OR PROGRESSION							
_							
☐ Previously reported							
☐ Previously reported ☐ No							
<u> </u>							

CIC: Unique Patient Number (UPN): SCT	Date:	уууу	 mm	dd
DISEASE AND PATIENT STATUS ON DA	ATE	LAS	Γ SEEN	١
LAST DISEASE STATUS				
☐ Complete remission (maintained or achieved) ☐ Unconfirmed ☐ Confirmed: ☐ By CT scan ☐ By PET ☐ Partial remission (> 50%) ☐ Progression			sponse (< death/No	< 50%) t evaluable
If Complete remission: Date of CR:yyyy mm dd				
SURVIVAL STATUS  Alive Dead				
PERFORMANCE SCORE (if alive)  Type of score used	fort) sional	assista	□ Not ev □ Unkno	
Cause of Death (if dead)				
☐ Relapse or progression ☐ Secondary malignancy ☐ HSCT related cause:				
(check as many as appropriate)	Yes	No	Unknow	'n
GvHD				··
Interstitial pneumonitis				
Pulmonary toxicity				
Infection: ☐ bacterial ☐ viral ☐ fungal ☐ parasitic ☐ unknown	一百			
Rejection / poor graft function				
Veno-Occlusive disease (VOD)				
Haemorrhage				
Cardiac toxicity				
Central nervous system toxicity				
Gastro intestinal toxicity				
Skin toxicity				
Renal failure				
Multiple organ failure				
EBV lymphoproliferative disease				
Other:				
Unknown				
Other:				
COMMENTS:				

IDENTIFICATION & SIGNATURE: